ESSA Pharma (EPIX) said late Thursday it decided to terminate the phase 2 trial evaluating the combination of masofaniten and enzalutamide in patients with metastatic castration-resistant prostate cancer compared with enzalutamide alone.
Shares slumped 71%, with intraday trading volume at over 27.6 million compared with a daily average of about 59,000.
Lexicon Pharmaceuticals (LXRX) said late Thursday that the Endocrinologic and Metabolic Drugs Advisory Committee of the US Food and Drug Administration voted 11-3 against recommending Zynquista (sotagliflozin) as an add-on to insulin therapy for glycemic control in adults suffering from type 1 diabetes and chronic kidney disease.
Shares sank 37% as intraday trading volume catapulted to more than 16.8 million from a daily average of about 2.7 million.
Autonomix Medical (AMIX) unveiled Friday the launch of a public offering of up to 698,812 common stock units at $14.31 each.
Shares retreated 24%, with intraday trading volume at over 341,000 versus a daily average of roughly 451,000.
Price: 1.52, Change: -3.68, Percent Change: -70.77
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.